Top 10 bhvi.org Wettbewerber

myopiainstitute.org

What is myopia? "A refractive error in which rays of light entering the eye parallel to the optic axis are brought to a focus in front of the retina when ocular accommodation is relaxed. This usually results from the eyeball being too long from front to back, but can be caused by an overly curved

endmyopia.org

The full directory of Jake Steiner’s podcast appearances on myopia reversal, vision improvement, and the EndMyopia method — 160+ episodes across health, science, and biohacking shows.

myopiaprofile.com

an information resource to help eye care practitioners control progression of myopia in clinical practice, including education courses, downloads and blogs

shileyeye.ucsd.edu

the shiley eye institute is the only academic institution in the san diego area with comprehensive programs for the clinical care of patients with eye disorders, cutting edge research on surgical techniques and treatments of eye diseases, education in the field of ophthalmology and innovative outreach to the community.

brienholdenfoundation.org

Within the community, where it matters. Home Acknowledgement of Country Brien Holden Foundation acknowledges the traditional Aboriginal custodians of the many lands that we live and work on, and their continuing connection to Country and culture. Australia Aboriginal and Torres Strait Islanders are three times more likely to have poor…

clspectrum.com

Michael Moore, BSc(Hons) Optom, MSc, PhD, is a lecturer at the Technological University Dublin. He also conducts groundbreaking research in myopia. We talked about his recent paper on the risk of unco...

bmjophth.bmj.com

Objective To evaluate the literature-pooled functional, anatomical and safety outcomes of aflibercept biosimilars compared with reference aflibercept for neovascular age-related macular degeneration (nAMD).Methods and analysis Systematic review and meta-analysis. Medline, Embase and CENTRAL were searched from inception to 2 June 2025. Phase 3 randomised controlled trials (RCTs) comparing aflibercept biosimilars with the reference product in patients with nAMD were included. Two independent reviewers conducted screening, data extraction, risk of bias (RoB 2) assessment and certainty of evidence assessment (Grading of Recommendations, Assessment, Development and Evaluation), with a third reviewer resolving discrepancies. Primary outcomes included mean difference (MD) change in best-corrected visual acuity (BCVA) and retinal thickness over time, risk ratio (RR) for proportion of participants gaining >15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and RR for adverse events. Meta-regression was used to evaluate the temporal stability of continuous outcomes.Results Six RCTs involving 2044 participants (1026 biosimilar, 1018 reference) were included. Five aflibercept biosimilars were evaluated, representing more than 50% of the eight biosimilars currently approved worldwide. Meta-regression revealed no significant difference in MD change in BCVA over time between biosimilar and reference aflibercept (slope: 0.0321 letters/week; p=0.1013). For MD change in retinal thickness, an initial anatomical advantage for reference aflibercept at week 0 (intercept: 9.58 µm; p=0.0449) was not sustained over time (slope: –0.1685 µm/week; p=0.2303). The pooled RR for gaining >15 ETDRS letters from baseline was 1.19 (95% CI 0.98 to 1.45; p=0.079). No statistically significant differences were observed across 15 safety outcomes.Conclusion This systematic review and meta-analysis found no statistically significant differences in functional, anatomical or safety outcomes betwee

jnjvisionpro.com

Use the sitemap on this page to learn how to navigate our website and easily find the information you are looking for about our brand

coopervision.com

We’re confident you’re going to love your CooperVision® contact lenses, but if you aren’t completely satisfied, rest assured, you have options!*

iapb.org

IAPB is the overarching alliance for the global eye health sector, with more than 150 organisations in over 100 countries working together for a world where everyone has universal access to eye care.